Recent Insider Transactions • Mar 15
Insider recently sold CA$54k worth of stock On the 9th of March, Krista McKerracher sold around 10k shares on-market at roughly CA$5.41 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth CA$157k. Insiders have been net sellers, collectively disposing of CA$375k more than they bought in the last 12 months. Annuncio • Mar 06
NervGen Pharma Corp. Announces Executive Changes NervGen Pharma Corp. appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President (SVP), Patient Advocacy and Clinical Affairs. Shamim Ruff brings more than 30 years of strategic leadership in regulatory affairs to NervGen, where she will oversee the company’s regulatory strategy and work closely with the executive team to support the realization of NervGen’s mission to transform the lives of individuals living with SCI. Most recently, Ms. Ruff served as Chief Regulatory Affairs Officer and SVP, Head of Quality Assurance at Stoke Therapeutics, leading regulatory strategy for the company's RNA medicine platform. Prior to Stoke, Ms. Ruff served as Chief Regulatory Affairs Officer at Sarepta Therapeutics, where she built the company's regulatory affairs and quality organizations and led regulatory strategy for its rare and infectious disease pipelines. She also served as Chair of the Development Advisory Board and Strategic Regulatory Advisor to the CEO and NDA Submissions Team at Soleno Therapeutics and on the Board of Directors of Reata Pharmaceuticals until its acquisition by Biogen. Her earlier career included leadership roles at Sanofi-Genzyme, Amgen, Abbott, and AstraZeneca. Ms. Ruff holds a master's degree in analytical chemistry from the University of Loughborough, U.K., and a bachelor's degree in chemistry and biology from the University of Leicester, U.K. Christine McSherry brings more than 30 years of experience bridging patient advocacy and clinical development. She will play a pivotal role in ensuring the voice of the SCI community is central to NervGen’s clinical strategy. Previously, Ms. McSherry co-founded Casimir, a clinical research organization that worked across more than 20 rare diseases, capturing and quantifying patient and caregiver perception of treatment benefit. Casimir's work pioneered the development of outcome measures to advance the FDA's patient-focused drug development initiative. Ms. McSherry served as CEO of Casimir until its acquisition by Emmes. In 2001, she founded the Jett Foundation, after the diagnosis of her son, Jett, with Duchenne muscular dystrophy (DMD). The Foundation became a leading voice for affected families and played a central role in the advocacy efforts that contributed to the FDA's approval of Exondys 51, the first approved therapy for DMD. Ms. McSherry continues to serve as a Director of the Jett Foundation and previously served on the Board of Directors of the Duchenne Alliance. She holds a BSN from Northeastern University and is a registered nurse. Recent Insider Transactions • Mar 03
Insider recently sold CA$109k worth of stock On the 2nd of March, Krista McKerracher sold around 20k shares on-market at roughly CA$5.46 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth CA$157k. Insiders have been net sellers, collectively disposing of CA$321k more than they bought in the last 12 months. Price Target Changed • Mar 01
Price target increased by 11% to CA$7.85 Up from CA$7.10, the current price target is an average from 2 analysts. New target price is 47% above last closing price of CA$5.35. Stock is up 94% over the past year. The company is forecast to post a net loss per share of CA$0.28 next year compared to a net loss per share of CA$0.36 last year. Recent Insider Transactions • Feb 24
Insider recently sold CA$157k worth of stock On the 20th of February, Krista McKerracher sold around 30k shares on-market at roughly CA$5.25 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$212k more than they bought in the last 12 months. Recent Insider Transactions • Feb 17
Insider recently sold CA$54k worth of stock On the 12th of February, Krista McKerracher sold around 10k shares on-market at roughly CA$5.45 per share. This transaction amounted to 9.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Annuncio • Feb 17
NervGen Pharma Corp., Annual General Meeting, Apr 23, 2026 NervGen Pharma Corp., Annual General Meeting, Apr 23, 2026. Location: ontario, toronto Canada Annuncio • Feb 14
NervGen Pharma Corp. Announces Executive Changes, Effective March 15, 2026 NervGen Pharma Corp. announced that William J. Adams tendered his resignation as Secretary and Principal Financial and Accounting Officer of the Company, due to his retirement. Mr. Adams' resignation is effective as of March 15, 2026. Mr. Adams' resignation was not the result of any disagreements with the Company, its management or the Company's Board of Directors. On February 12, 2026, the Board approved the appointment of Dr. Adam Rogers as the Company's Principal Financial and Accounting Officer, effective as of March 15, 2026. Annuncio • Feb 13
NervGen Pharma Corp. Announces CFO Changes, Effective March 15, 2026 NervGen Pharma Corp. announced that Bill Adams will retire as Chief Financial Officer, effective March 15, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition. On February 12, 2026, the Board approved the appointment of Dr. Adam Rogers as the Company’s interim Chief Financial Officer and the Company’s Principal Financial and Accounting Officer, effective as of March 15, 2026. Breakeven Date Change • Jan 02
Forecast to breakeven in 2028 The 2 analysts covering NervGen Pharma expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$1.09m in 2028. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Recent Insider Transactions Derivative • Jul 24
Co-Founder & Independent Director exercised options to buy CA$186k worth of stock. On the 18th of July, Harold Punnett exercised options to buy 50k shares at a strike price of around CA$2.70, costing a total of CA$135k. This transaction amounted to 4.4% of their direct individual holding at the time of the trade. Since December 2024, Harold has owned 1.13m shares directly. Company insiders have collectively bought CA$295k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Jul 11
Independent Director exercised options to buy CA$198k worth of stock. On the 9th of July, Brian Bayley exercised options to buy 50k shares at a strike price of around CA$2.70, costing a total of CA$135k. This transaction amounted to 19% of their direct individual holding at the time of the trade. Since December 2024, Brian's direct individual holding has decreased from 400.00k shares to 315.00k. Company insiders have collectively bought CA$160k more than they sold, via options and on-market transactions, in the last 12 months. Annuncio • Jul 02
NervGen Pharma Corp. Announces Resignation of Daniel Mikol, MD, Ph.D as Chief Medical Officer NervGen Pharma Corp. announced resignation of Daniel Mikol, MD, Ph.D as Chief Medical Officer in order to pursue new opportunities. Randall Kaye, MD, who was recently appointed Chief Medical Advisor, will increase the scope of his role as the company initiates a search for Dr. Mikol's replacement. Price Target Changed • Jun 17
Price target increased by 23% to CA$8.83 Up from CA$7.15, the current price target is an average from 4 analysts. New target price is 154% above last closing price of CA$3.48. Stock is up 53% over the past year. The company is forecast to post a net loss per share of CA$0.31 next year compared to a net loss per share of CA$0.36 last year. New Risk • Jun 02
New major risk - Revenue and earnings growth Earnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$18m free cash flow). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Annuncio • Jun 02
NervGen Pharma Corp. Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury NervGen Pharma Corp. announced positive Topline results from the chronic cohort (1-10 years post injury) of its Phase 1b/2a clinical trial evaluating its lead drug candidate, NVG-291, as a potential treatment for spinal cord injury. The double-blind, placebo-controlled proof-of-concept Phase 1b/2a Clinical trial (NCT05965700) evaluates the safety and efficacy of NVG-291 in two separate cohorts of individuals with cervical motor incomplete spinal cord injury: chronic (1-10 years post-in injury) and subacute (20-90 days post-in injury), given demonstrated efficacy in preclinical models of both chronic and acute spinal cord injury. The trial is being partially funded by a grant from Wings for Life, which is being provided in several milestone-based payments and will offset a portion of the direct costs of this clinical trial. NervGen has received Fast Track designation from the FDA for NVG-291 in individuals with spinal cord injury. The company is testing the clinical efficacy of its lead candidate, NVG-291. in a Phase 1b/2 a clinical trial in spinal cord injury and has initiated preclinical test of concept evaluation of pipeline candidate, NVG-300, in models of neurotrauma and spinal cord injury. As the first pharmaceutical candidate to show improved motor recovery based on increased motor evoked potential amplitude, these study results represent a significant scientific advance and step forward in the potential to treat SCI, where there remains no approved pharmaceuticals to enable sustained functional recovery. Topline safety and efficacy results reinforce the potential of NVG-291 to promote nervous system repair in individuals living with traumatic cervical SCI, the expected benefits of changes in upper extremity motor function for individuals living with SCI and the potential to otherwise treat SCI. New Risk • May 15
New major risk - Revenue and earnings growth Earnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$17m free cash flow). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Price Target Changed • Apr 17
Price target increased by 11% to CA$4.98 Up from CA$4.50, the current price target is an average from 4 analysts. New target price is 68% above last closing price of CA$2.96. Stock is up 48% over the past year. The company is forecast to post a net loss per share of CA$0.32 next year compared to a net loss per share of CA$0.36 last year. New Risk • Apr 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$17m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$17m free cash flow). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Annuncio • Mar 05
NervGen Pharma Corp., Annual General Meeting, May 06, 2025 NervGen Pharma Corp., Annual General Meeting, May 06, 2025. Location: ontario, toronto Canada Annuncio • Feb 08
NervGen Pharma Corp. Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury NervGen Pharma Corp. announced that the first subject has been enrolled and dosed in the subacute cohort of its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) evaluating its lead candidate, NVG-291, in individuals with spinal cord injury (SCI). The company previously reported the completion of enrollment of the chronic cohort and announced that results for the chronic cohort are expected in Second Quarter 2025. Recently, the company received IRB approval for an amendment focused on the subacute cohort of the Phase 1b/2a clinical trial. Key changes to the protocol were implemented to facilitate enrollment, for example, revising the timing of subacute SCI to 20 to 90 days post-injury, and to decrease the burden on study participants by reducing the number of visits and assessments. About Phase 1b/2a Trial. The double-blind, placebo-controlled proof-of-concept Phase 1b/2aclinical trial (NCT05965 700) evaluates the safety and efficacy of NVG-291 in two separate cohorts of individuals with cervical spinal cord injury: chronic (1-10 years post-injury) and subacute (20-90 days post-injury), given demonstrated efficacy in preclinical models of both chronic and acute spinal cord injury. The trial is designed to evaluate the efficacy of a fixed dose of NVG-291 using multiple clinical outcome measures as well as objective electrophysiological and MRI imaging measures and blood biomarkers that together will provide comprehensive information about the extent of recovery of function, with a focus on improvements in motor function. The trial is being partially funded by a grant from Wings for Life, which is being provided in several milestone-based payments and will offset a portion of the direct costs of this clinical trial. NVG-291 has received Fast Track designation in spinal cord injury from the U.S. Food and Drug Administration. Annuncio • Jan 02
NervGen Pharma Corp. Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury NervGen Pharma Corp. announced that it has enrolled the 20th and final subject in the chronic cohort of its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) evaluating its lead candidate, NVG-291, in individuals with spinal cord injury (SCI). Furthermore, the company has received IRB approval for an amendment to its Phase 1b/2 a clinical trial and has initiated the screening of subjects for the subacute cohort of the study. The double-blind, placebo-controlled proof-of-concept Phase 1b/2a clinical trial (NCT059 65700) evaluates the safety and efficacy of NVG-291 in two separate cohorts of individuals with cervical spinal cord injury: chronic (1-10 years post-injury) and subacute (20-90 days post-injury), given demonstrated efficacy in preclinical models of both chronic and acute spinal cord injury. The trial is designed to evaluate the efficacy of a fixed dose of NVG-291 using multiple clinical outcome measures as well as objective electrophysiological and MRI imaging measures and blood biomarkers that together will provide comprehensive information about the extent of recovery of function, with a focus on improvements in motor function. Specifically, the primary objective is to assess the change in corticospinal connectivity of defined upper and lower extremity muscle groups following treatment based on changes in motor evoked potential amplitudes. Secondary objectives are to evaluate changes in a number of clinical outcome assessments focusing on motor function and strength, as well as changes in additional electrophysiological measurements. The cohorts will be comprised of approximately 20 subjects each and will be evaluated independently as the data becomes available. The trial is being partially funded by a grant from Wings for Life, which is being provided in several milestone-based payments and will offset a portion of the direct costs of this clinical trial. Annuncio • Dec 20
NervGen Pharma Corp. has filed a Follow-on Equity Offering in the amount of CAD 30 million. NervGen Pharma Corp. has filed a Follow-on Equity Offering in the amount of CAD 30 million.
Security Name: Common Shares
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • Dec 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$16m free cash flow). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • Nov 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$16m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$16m free cash flow). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). Board Change • Oct 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO, President & Director Mike Kelly was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jul 25
NervGen Pharma Corp. Appoints Neil Klompas to Board of Directors NervGen Pharma Corp. announced the appointment of Mr. Neil Klompas to the company's Board of Directors. Mr. Klompas is an experienced life sciences and healthcare sector executive and board member, who recently served as President and Chief Operating Officer of Zymeworks Inc. During his time with the company, he oversaw finance and operations executing the company's initial public offering on the NYSE and TSX. Prior to Zymeworks, Mr. Klompas worked with KPMG LLP as part of the Pharmaceutical, Biotech Medical Devices MA Transaction Services practice in Princeton, NJ, and with KPMG LLP in the life sciences assurance practice based in Vancouver. Mr. Klompas has served as Board Chair for Ovensa Inc., and as the Chair of the Audit Committee and Special Committee of Liminal Biosciences Inc. until its acquisition in 2023. He holds his BSc in Microbiology Immunology from the University of British Columbia and is a Chartered Professional Accountant. The company also announced that it has granted 150,000 incentive stock options to Mr. Klompas exercisable at a price of $2.85 per share for a period of five years and that vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan. Board Change • Jun 10
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO, President & Director Mike Kelly was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jun 06
NervGen Pharma Corp. Approves Board and Audit Committee Elections NervGen Pharma Corp. at the AGM held on June 4, 2024, approved to appoint John Ruffolo as the new Chair of Audit Committee. As the Founder and Managing Partner of Maverix Private Equity, founder of OMERS Ventures and a Fellow of the Chartered Professional Accountants, John's experience is a great fit to support NervGen's growth. Glenn Ives was elected by his fellow Board members as Chair of the Board following the AGM. As a past Chair of Deloitte Canada and the Deloitte Global Risk Committee, Glenn's experience is well suited to lead NervGen's board as they advance their programs into later-stage clinical development. New Risk • May 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: CA$135.0m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$11m free cash flow). Negative equity (-CA$2.0m). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (CA$135.0m market cap, or US$99.1m). New Risk • Apr 17
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$2.0m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$11m free cash flow). Negative equity (-CA$2.0m). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). Recent Insider Transactions • Mar 31
CEO, President & Director recently bought CA$338k worth of stock On the 28th of March, Michael Kelly bought around 144k shares on-market at roughly CA$2.35 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months. New Risk • Mar 23
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: CA$135.9m (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$13m free cash flow). Earnings have declined by 32% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Significant insider selling over the past 3 months (CA$450k sold). Market cap is less than US$100m (CA$135.9m market cap, or US$99.8m). Recent Insider Transactions Derivative • Mar 14
Independent Director exercised options to buy CA$272k worth of stock. On the 12th of March, Brian Bayley exercised options to buy 100k shares at a strike price of around CA$1.00, costing a total of CA$100k. This transaction amounted to 33% of their direct individual holding at the time of the trade. Since June 2023, Brian has owned 450.00k shares directly. Company insiders have collectively bought CA$201k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Feb 29
Co-Founder & Independent Director exercised options to buy CA$347k worth of stock. On the 22nd of February, Harold Punnett exercised options to buy 100k shares at a strike price of around CA$1.00, costing a total of CA$100k. This transaction amounted to 10.0% of their direct individual holding at the time of the trade. Since June 2023, Harold has owned 1.00m shares directly. Company insiders have collectively bought CA$101k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Feb 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$13m free cash flow). Earnings have declined by 32% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). Annuncio • Oct 26
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury NervGen Pharma Corp. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its proprietary lead compound, NVG-291, in individuals with spinal cord injury (SCI). FDA's Fast Track program is designed to facilitate the development of drugs intended to treat serious conditions and fill unmet medical needs as part of the FDA's goal to get important new drugs to patients earlier. Fast Track also provides eligibility for both Priority Review, which can shorten the New Drug Development (NDA) review process, and for Accelerated Approval, which can allow for an earlier or faster approval based on a surrogate or intermediate clinical endpoint. Annuncio • Oct 18
Nervgen Pharma Appoints John Ruffolo to Board of Directors NervGen Pharma appointed John Ruffolo to Board of Directors . He has Extensive experience in private equity, venture capital and advising high growth, innovative companies, Brings personal experience and knowledge of spinal cord injury to NervGen's board, Important board addition joins as Company advances clinical milestone with Phase 1b/2a study of NVG-291 underway. John Ruffolo is the Founder and Managing Partner of Maverix Private Equity, a private equity firm focused on innovation-enabled growth and disruption investment strategies. Previously he founded OMERS Ventures, the venture capital arm of the large Ontario pension fund where he led early investments in startup success stories such as Shopify Inc. He has also championed Canada's technology industry as a co-founder of the Council of Canadian Innovators, along with former Research in Motion co-CEO Jim Balsillie. As an active board member in the profit and not-for-profit sectors, John currently works with many leading innovative organizations includingAI Partnerships Corp., engineering.com, OneEleven, the Rick Hansen Foundation, the CIBC Foundation, Caldwell's Top 40 Under 40, the Investigative Journalism Foundation, and the Dean's Global Council for the Schulich School of Business. The Company also announced that it has granted 150,000 incentive stock options to Mr. Ruffolo exercisable at a price of $1.75 per share for a period of five years and that vest equally every three months over a one-year period. Annuncio • Sep 26
NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury NervGen Pharma Corp. announced the first subject has been dosed in the Company's landmark Phase 1b/2a proof-of-concept placebo-controlled clinical trial for its proprietary lead compound, NVG-291, in individuals with spinal cord injury (SCI). Given there are approximately 300,000 people with SCI living in the United States alone, the limited number of clinical trials in this area and the tremendous anticipation for this trial within the SCI community, recruitment for the chronic cohort (1-10 years post injury) is anticipated to happen relatively quickly with results expected by mid-2024. Results from the subacute cohort (10-49 days post-injury) are expected in late 2024/early 2025. The trial is being conducted at Shirley Ryan AbilityLab in Chicago. Price Target Changed • May 25
Price target increased by 8.6% to CA$6.00 Up from CA$5.53, the current price target is provided by 1 analyst. New target price is 257% above last closing price of CA$1.68. Stock is down 22% over the past year. The company posted a net loss per share of CA$0.39 last year. Annuncio • Feb 16
NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291 NervGen Pharma Corp. announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial of the Company's proprietary lead compound, NVG-291, have completed dosing. The Company now plans to initiate a Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury in Third Quarter 2023. Based on the encouraging results from preclinical studies, the Company plans to evaluate the efficacy of NVG- 291 versus placebo in two cohorts: individuals with a chronic injury (1-10 years post-injury) and individuals with a subacute injury (10-49 days post-injury). In preclinical studies of spinal cord injury, NervGen's NVG-291 has been demonstrated to promote neural repair mechanisms, including axonal regeneration, remyelination and plasticity. Board Change • Nov 16
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Independent Director Harold Punnett is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Oct 27
Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291 NervGen Pharma Corp. announced that the U.S. Food and Drug Administration (FDA) has amended the partial clinical hold to permit the inclusion of males and premenopausal females at certain dose levels in the Company's Phase 1 clinical trial of NervGen's proprietary compound, NVG-291. A partial clinical hold was placed on NVG-291 by the FDA in March 2020 when adverse dose- dependent reproductive organ toxicity results were observed in initial 7-day and 28-day preclinical toxicology studies. Under the partial clinical hold, NervGen was permitted to enroll females and postmenopausal females in the single ascending dose (SAD) and MAD portions of the study, respectively, and recently completed enrollment of the third and final MAD dose cohort. The FDA requested additional preclinical safety data prior to inclusion of males and premenopausal females in the Phase 1 program. NervGen conducted the preclinical studies requested by the FDA, in addition to conducting longer 13-week studies. Results from the follow-up preclinical studies did not show adverse reproductive organ toxicity effects, including a repeat 28-day study, a 13-week study, and female and male fertility and early embryonic development studies. After the third and final dose cohort of postmenopausal females is completed, bridging cohorts of males and premenopausal females will be evaluated. The additional preclinical safety studies requested by the FDA will further investigate the preclinical safety margin of NVG-291, testing exposures of NVG-291 higher than those tested in the follow-up preclinical safety studies. Pending successful completion of these preclinical safety studies and provision of available data from the ongoing Phase 1 study to the FDA, NervGen will seek full removal of the partial clinical hold. Annuncio • Oct 13
NervGen Pharma Corp. Receives Up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury NervGen Pharma Corp. announced it has been awarded up to USD 1.5 million in US Department of Defense (DoD) funding from the Military Operational Medicine Research Program (MOMRP/JPC-5) to evaluate NervGen's NVG-291-R as a therapeutic to enable accelerated and enhanced restoration of function following peripheral nerve injury. The work described in the project would establish preclinical proof-of-concept for the use of NVG-291-R to improve the rate and extent of nerve regeneration following peripheral nerve crush injury or transection followed by repair. There are currently no effective pharmaceutical treatments to enhance recovery in PNI. The funding was made through the US Army Medical Research and Development Command's (USAMRDC) Other Transaction Agreement with the Medical Technology Enterprise Consortium (MTEC). MTEC is an enterprise partnership in collaboration with industry and academia to facilitate research and development activities in cooperation with the DoD and other government agencies in the biomedical sciences. NervGen will be working with Wilson "Zack" Ray, MD, a Professor of Neurosurgery, Orthopedic Surgery, and Biomedical Engineering at Washington University in St. Louis, to evaluate the investigational therapeutic NVG-291-R. The objectives of the research program are: (i) to investigate functional and histological recovery following treatment with NVG-291-R in different animal models of PNI, (ii) to identify the best dosing regimen for NVG-291-R to advance to a clinical study in patients with PNI, and (iii) to identify where NVG-291-R may be exerting therapeutic benefits (e.g., enhancing regeneration through lesion, rate of regeneration, remyelination of axons, plasticity in CNS). Annuncio • Jul 23
NervGen Pharma Corp., Annual General Meeting, Sep 28, 2022 NervGen Pharma Corp., Annual General Meeting, Sep 28, 2022. Annuncio • Jul 16
NervGen Pharma Corp. announced that it has received $15.225 million in funding from PFP Biosciences Holdings On July 14, 2022, NervGen Pharma Corp. closed the transaction. The transaction included participation from new investor, PFP Biosciences Holdings for $15,000,000 and acquired 10,000,000 units. As a part of the transaction, Adam Rogers, of PFP Biosciences Holdings will join the company's board of directors. The company paid certain finders a fee of 500,000 common shares at a price per share valued at the unit price. PFP Biosciences Holdings owns and controls 10,000,000 common shares representing 17.1% of the issued and outstanding common shares of the company based on a total of 58,544,558 common shares outstanding as of July 13, 2022 and 5,000,000 warrants. Each warrant contains a restriction that the holder may not exercise the warrant if the holder owns more than 19.99% of the company at the time of exercise.
The TSX Venture Exchange has accepted for filing documentation with respect to the transaction. The transaction included participation from 2 placees. The company paid finder’s fee to MRC Advisors LLC received 500,000 shares at $1.50 per share. Annuncio • Jul 15
NervGen Pharma Corp. Appoints Adam Rogers to its Board of Directors NervGen Pharma Corp. announced that Adam Rogers has been appointed to NervGen's Board of Directors. Adam Rogers, MD is a Principal of PFP Biosciences Holdings and a board-certified ophthalmologist specializing in diseases and surgery of the retina and vitreous. Dr. Rogers co-founded Hemera Biosciences in 2010. He assumed the role of Chief Executive Officer in 2017 and oversaw all aspects of the company until the Hemera assets were acquired in December 2020 by Janssen Pharmaceuticals, a subsidiary of Johnson &Johnson. Dr. Rogers graduated from Emory University College and Emory School of Medicine. From 2001 to 2020 he served as an Assistant Professor of Ophthalmology at the New England Eye Center of Tufts Medical Center (Boston, MA). Dr. Rogers has published 25 articles in peer reviewed journals and co-authored two textbooks and numerous chapters in major ophthalmic textbooks. Since 2007 he has served on the board of One Family Inc. He is a member of the Emory University Board of Trustees. Annuncio • Jul 01
NervGen Pharma Corp. announced that it expects to receive $15.225 million in funding NervGen Pharma Corp. announced a non-brokered private placement of 10,150,000 units at a price of $1.50 per unit for gross proceeds of $15,225,000. Each unit consists of one common share in the capital of the company and one-half of one common share purchase warrant. Each warrant will be exercisable into one common share at a price of $1.75 per common share for a period of 60 months after closing. The company may pay a finder's fee of 5% in the transaction. The units will be subject to a four month and one day hold period in accordance with applicable Canadian securities laws. The transaction is expected to close on or about July 8, 2022, or as per the approval of the TSXV. Annuncio • May 13
Nervgen Pharma Corp. Receives Approval from the Safety Review Committee to Advance to the Third and Highest Dose Cohort in the Multiple Ascending Dose Portion of Phase 1 Clinical Trial of the Company's Proprietary Lead Compound, NVG-291 NervGen Pharma Corp. announced it has received approval from the Safety Review Committee to advance to the third and highest dose cohort in the multiple ascending dose (MAD) portion of its Phase 1 clinical trial of the Company's proprietary lead compound, NVG-291. In preclinical animal studies, NVG-291 has demonstrated the potential to promote repair mechanisms in the nervous system, including axonal regeneration, remyelination, and plasticity. The Company also reported its financial and operational results for the first quarter ended March 31, 2022. NervGen will now proceed to evaluate the highest dose level of NVG-291 in the third MAD cohort. This next step will provide greater flexibility in establishing doses for future patient studies and will provide additional important information about the safety and pharmacokinetic profile of NVG-291. Following completion of the third MAD dose cohort and ongoing toxicology studies requested by the United States Food and Drug Administration (FDA), NervGen will seek removal of the partial clinical trial hold initiated by the FDA and evaluate bridging cohorts of healthy males and healthy premenopausal females. Recent Insider Transactions Derivative • May 07
President exercised options to buy CA$112k worth of stock. On the 4th of May, Paul Brennan exercised options to buy 50k shares at a strike price of around CA$1.60, costing a total of CA$80k. This transaction amounted to 8.8% of their direct individual holding at the time of the trade. Since June 2021, Paul has owned 569.35k shares directly. Company insiders have collectively bought CA$531k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Apr 28
Independent Director exercised options to buy CA$224k worth of stock. On the 26th of April, Brian Bayley exercised options to buy 100k shares at a strike price of around CA$1.60, costing a total of CA$160k. This transaction amounted to 29% of their direct individual holding at the time of the trade. Since June 2021, Brian has owned 350.00k shares directly. Company insiders have collectively bought CA$214k more than they sold, via options and on-market transactions, in the last 12 months. Board Change • Apr 27
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Harold Punnett is the most experienced director on the board, commencing their role in 2017. Independent Director Randall Kaye was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Annuncio • Apr 14
NervGen Pharma Corp. Announces Executive Changes NervGen Pharma Corp. announced the appointment of Craig Thompson to NervGen's Board of Directors. Mr. Thompson was most recently President & Chief Executive Officer and a member of the Neurana Pharmaceuticals board of directors. Previously Mr. Thompson was President & Chief Executive Officer of Anthera Pharmaceuticals, Chief Operating Officer for Tetraphase Pharmaceuticals and Chief Commercial Officer for Trius Therapeutics. NervGen also announced that in conjunction with Mr. Thompson joining the Board, Dr. Michael Abrams will be resigning, effective immediately. Board Change • Jan 14
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Member of Alzheimer's Disease Scientific Advisory Board Jeff Cummings was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annuncio • Nov 30
NervGen Pharma Corp. announced that it has received CAD 2.321075 million in funding NervGen Pharma Corp. announced a non-brokered private placement of 892,721 units at a price of CAD 2.60 per unit for gross proceeds of CAD 2,321,075 on November 29, 2021. Each unit issued in the private placement consisted of one common share and one-half of one common share purchase warrant. Each warrant is exercisable into one common share at a price of CAD 3.20 per common share until November 29, 2023. All of the securities issued pursuant to the private placement are subject to a four-month and one-day hold period in accordance with applicable Canadian securities laws. The transaction included participation from shareholders of the company including one director of the company. In connection with the private placement and in accordance with the policies of the TSX Venture Exchange, the company paid certain finders a cash fee totaling CAD 20,430. Annuncio • Aug 06
NervGen Pharma Corp. announced that it has received CAD 2.343036 million in funding NervGen Pharma Corp. (TSXV:NGEN) announced a non-brokered private placement of 1,511,636 units at an issue price of CAD 1.55 per unit for gross proceeds of CAD 2,343,036 on August 5, 2021. Each unit consist of one common share and one-half common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at a price of CAD 2.10 per share until August 4, 2023. The transaction included participation from co-founder Brian McAlister for 200,000 units, Rich Macary for 50,000 units. The company paid finders fees of CAD 45,570 and issued 29,400 common share purchase warrants. All securities issued in the transaction have a hold period of four months and one day. Annuncio • May 13
NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 5.0375 million. NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 5.0375 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 3,250,000
Price\Range: CAD 1.55
Discount Per Security: CAD 0.093 Annuncio • May 07
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291 NervGen Pharma Corp. announce that the first subject has been dosed with NVG-291 in the Company's Phase 1 clinical trial in healthy volunteers. The Phase 1 study with NVG-291 is being conducted in Australia via Novotech (Australia) Pty Limited, a leading full-service contract research organization. The study, conducted in healthy subjects, is a two- part, triple-blind, randomized, placebo-controlled, first-in-human study. Part one of the study is the single ascending dose portion of the trial and will be conducted in females. Part two of the study is the multiple ascending dose portion of the trial and will be conducted in post-menopausal females. The primary objective of the trial is to evaluate the safety, tolerability, and pharmacokinetics of NVG-291. Upon completion of the multiple ascending dose portion of the trial in heathy subjects, NervGen intends to initiate a multi-dose Alzheimer's disease patient cohort as a Phase 1b program. Concurrently, the Company also plans to initiate Phase 2 trials in spinal cord injury and multiple sclerosis with each of these trials planned to start in 2022. NVG-291 is an inhibitor of PTP, a promising target for reducing the clinical effects of nerve damage, either as a result of trauma, such as in the case of spinal cord injury, traumatic brain injury or stroke, or neurodegenerative diseases, such as multiple sclerosis or Alzheimer's disease. NervGen believes that inhibiting the activity of PTP has the potential to promote nerve repair mechanisms such as nerve regeneration, remyelination and plasticity; promote autophagy, a cellular self-cleaning mechanism; and to promote a non-inflammatory phenotype in microglia cells, the innate immune cells of the brain. Annuncio • Mar 05
NervGen Pharma Corp. Provides Regulatory Update on Development Program for NVG-291 NervGen Pharma Corp. provided a regulatory program update for NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTP") inhibitor being developed for the treatment of spinal cord injury, multiple sclerosis and Alzheimer's disease. NervGen has been cleared by the FDA to proceed with the single ascending dose ("SAD") portion of the trial in females, and the multiple ascending dose ("MAD") portion of the trial in post-menopausal females. The FDA has asked for additional preclinical safety data prior to including males in the Phase 1 program, and prior to including premenopausal females in the MAD portion of the trial. NervGen plans to initiate its first Phase 1 clinical trial in Australia under all of the conditions required by the FDA. Prior to dosing in Australia, NervGen must also obtain final approval from the ethics review board governing the study and provide notification to the Therapeutic Goods Administration. The Company will modify its proposed Phase 1 protocol and now expects to dose the first human subjects in this program in Second Quarter 2021 in Australia after all requisite approvals have been obtained. Pending a positive outcome of the Phase 1 results in healthy volunteers, NervGen intends to add a multi-dose Alzheimer's disease patient cohort to the Phase 1 program. The Company also plans to initiate Phase 2 trials in spinal cord injury and multiple sclerosis after completion of Phase 1 and after resolution of the partial clinical hold. NervGen currently expects it will be able to initiate these trials in the first half of 2022. Is New 90 Day High Low • Jan 23
New 90-day high: CA$2.41 The company is up 37% from its price of CA$1.76 on 23 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 74% over the same period. Is New 90 Day High Low • Dec 18
New 90-day high: CA$1.90 The company is up 19% from its price of CA$1.59 on 18 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 51% over the same period. Is New 90 Day High Low • Nov 06
New 90-day high: CA$1.85 The company is up 11% from its price of CA$1.67 on 07 August 2020. The Canadian market is flat over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 15% over the same period. Annuncio • Oct 29
NervGen Pharma Corp. Appoints Dr. Randall Kaye to the Company's Board of Directors NervGen Pharma Corp. announced that it has appointed Dr. Randall Kaye to the Company's Board of Directors. Dr. Kaye brings over 25 years of industry experience addressing high unmet medical need disease areas. He has significant leadership experience in senior roles where he has provided medical and scientific perspective in clinical development medical affairs. He is currently and has previously served in Chief Medical Officer (CMO) roles overseeing clinical research programs and development, including those with a specific focus on developing novel therapies for central nervous system disorders. Presently, Dr. Kaye is the CMO at Neurana Pharmaceuticals Inc., a Phase 3 company developing a novel treatment for acute and painful muscle spasms. Annuncio • Oct 02
NervGen Pharma Corp. Provides an Update on NVG-291 NervGen Pharma Corp. provided an update on the development plans for its lead compound, NVG-291, in three primary indications: multiple
sclerosis, spinal cord injury and Alzheimer's disease. The NVG-291 development program is planned as: Phase 1 clinical trial in healthy volunteers remains on track to begin in 2020 in Australia; Phase 2 clinical trials in multiple sclerosis and spinal cord injury (sub-acute and chronic) are expected to begin in the second half of 2021; and preclinical results in multiple sclerosis, Alzheimer's disease, chronic spinal cord injury and other disease models are expected to roll out starting in the next months and continue throughout 2021. Is New 90 Day High Low • Sep 24
New 90-day low: CA$1.43 The company is down 35% from its price of CA$2.20 on 26 June 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. Annuncio • Aug 11
NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 6.45 million. NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 6.45 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 3,685,714
Price\Range: CAD 1.75
Discount Per Security: CAD 0.1225